Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in people with Parkinson’s disease; biomarker analysis to be conducted in Q2 2025 BETHESDA, Md ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback